

# **LIST OF REFERENCES CITED BY APPLICANT** (Use several sheets if necessary)

<b>Application Number</b>	10/576,138
<b>Filing Date</b>	April 14, 2006
<b>First Named Inventor</b>	Zeldis
<b>Art Unit</b>	1614
<b>Examiner Name</b>	Anderson, James D.
<b>Attorney Docket No.</b>	9516-352-999

## **U.S. PATENT DOCUMENTS**

*Examiner Initials	Cite No.	Document Number – Kind Code	Publication Date mm/dd/yyyy	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

## **FOREIGN PATENT DOCUMENTS**

*Examiner Initials	Cite No.	Foreign Patent Document Country Code, Number, Kind Code (if known)	Publication Date mm/dd/yyyy	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T
	B08	EP 1 676 577	07/05/2006	Celgene Corporation		

## **NON PATENT LITERATURE DOCUMENTS**

*Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
	C186	Raza, A. <i>et al.</i> , "Thalidomide as a Single Agent or in Combination with Topotecan, Pentoxifylline and/or Enbrel in Myelodysplastic Syndromes (MDS)," <i>Blood, American Society of Hematology</i> , Nov 2000, 11(96):146A	
	C187	Copy of communication in corresponding EP Patent Application No. 04800842.9	

NYI-4159200v1

<b>EXAMINER SIGNATURE</b>	<b>DATE CONSIDERED</b>
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	